A Georgia overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
35.4% of Georgia adults have obesity, per the CDC's 2024 BRFSS data 6, across a state of 11,180,878 residents 7.
Georgia's uninsured rate is 12.0% (ACS 2024 1-year) 8, and the state's Medicaid program is narrower than most — two facts that decide the coverage answer before the drug list is even opened.
Georgia has not expanded Medicaid under the ACA. In its place, the state runs a narrow Section 1115 waiver, Georgia Pathways to Coverage, created by the Patients First Act (signed 3/27/2019, CMS-approved 10/15/2020, extension request filed 1/17/2025) 10 — most low-income childless adults have no Medicaid pathway at all, obesity coverage aside.
On top of that gap, Georgia Medicaid Fee-for-Service does not cover Wegovy or Zepbound — the two GLP-1/GIP drugs FDA-approved specifically for chronic weight management — for any adult. A full-text search of the complete 2026 Preferred Drug List (effective 8/1/26, updated 8/12/26) found neither brand name anywhere in either the 76-page therapeutic-class or 69-page drug-name version 12. GLP-1/GIP agents appear on the PDL only in the diabetes-focused antidiabetic class: Ozempic, Mounjaro, and Victoza/generic liraglutide are Preferred with prior authorization; Rybelsus and Trulicity are Non-Preferred with PA 13. The only obesity-specific drugs on the list, Saxenda and Xenical, are explicitly age-gated to patients 12–17 and unavailable to adults 12.
DCH's prior-authorization criteria index has no anti-obesity criteria document at all 5, consistent with the class being excluded rather than merely restricted 4. For the roughly 1.3 million uninsured adult Georgians and the state's Medicaid population alike, cash-pay telehealth is the only access route to GLP-1 obesity treatment.
Astra's pricing is the same in every state we serve: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans, or $145 and $250 per month when billed monthly. There is no local price list, no regional surcharge, and no state-specific discount.
That is the same figure in Atlanta, Augusta, Savannah, and every other state Astra serves — median household income in Georgia is $79,991 (ACS 2024 1-year) 8, and we do not price against what a given market will bear.
Georgia's 159 counties are the second-most of any US state, after Texas 9, and population and care access are dispersed well beyond metro Atlanta as a result. Endocrinology and weight-management specialist capacity is concentrated in a handful of urban centers, leaving much of the state — including mid-size hubs like Augusta and Savannah — without easy in-person access to an obesity specialist. Telehealth removes the distance requirement entirely: an Astra clinician can prescribe and manage GLP-1 treatment for a patient anywhere in Georgia without an in-person visit.
Verification pending: HRSA Health Professional Shortage Area counts for Georgia were not obtained this pass — the data.hrsa.gov HPSA-find endpoint returned 404 and the shortage-area export requires an interactive form rather than a plain GET. No HPSA count is published here until it is pulled.
Physicians treating Georgia patients are licensed and regulated by the Georgia Composite Medical Board.
TODO — unverified: the board's specific telehealth prescribing rule (real-time exam requirement, out-of-state reciprocity) was not confirmed this pass, so this page asserts none.
Astra is licensed to treat patients in Georgia and all 50 states.
Astra treats patients in Georgia through state-licensed physicians.
City-level obesity, coverage, and local pricing detail for Augusta and Savannah.
No. As of August 2026, neither Wegovy nor Zepbound appears anywhere on Georgia Medicaid's 2026 Preferred Drug List. GLP-1/GIP drugs are covered only for diabetes (Ozempic, Mounjaro, Victoza, with prior authorization), and the two obesity-specific drugs that are on the list, Saxenda and Xenical, are restricted to patients ages 12–17. Adults have no Medicaid pathway to GLP-1 obesity treatment in Georgia.
No — Astra's price is the same nationwide. Semaglutide is $68/month and tirzepatide is $118/month, both on 12-month plans ($816 and $1,416 paid annually), whether you're in Atlanta, Augusta, Savannah, or any other state Astra serves.
Two separate gaps compound here. Georgia has not expanded Medicaid under the ACA and instead runs the limited Pathways to Coverage waiver, so many low-income adults have no Medicaid at all. Separately, the state's Preferred Drug List treats GLP-1/GIP drugs strictly as diabetes medications — Wegovy and Zepbound do not appear in the 2026 PDL for any age group.
Yes. With roughly 1.3 million uninsured adults statewide and no Medicaid route to GLP-1 obesity drugs even for those with coverage, cash-pay telehealth is the primary access path. Astra's plans start at $68/month for semaglutide and $118/month for tirzepatide, billed on a 12-month term.
Yes. Astra is licensed to treat patients in all 50 states, including every county in Georgia. That matters here more than most places: Georgia has 159 counties, the second-most in the US, so care is spread thin outside metro Atlanta. Telehealth closes that gap for cities like Augusta and Savannah without requiring a trip to a specialist.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.